CN104862372A - Selective medium with fusobacterium nucleatum - Google Patents
Selective medium with fusobacterium nucleatum Download PDFInfo
- Publication number
- CN104862372A CN104862372A CN201510343563.5A CN201510343563A CN104862372A CN 104862372 A CN104862372 A CN 104862372A CN 201510343563 A CN201510343563 A CN 201510343563A CN 104862372 A CN104862372 A CN 104862372A
- Authority
- CN
- China
- Prior art keywords
- calf serum
- fusobacterium nucleatum
- agar
- thermal distortion
- aseptic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000605986 Fusobacterium nucleatum Species 0.000 title claims abstract description 35
- 239000006152 selective media Substances 0.000 title abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 49
- 244000309466 calf Species 0.000 claims abstract description 36
- 210000002966 serum Anatomy 0.000 claims abstract description 36
- 229920001817 Agar Polymers 0.000 claims abstract description 35
- 239000008272 agar Substances 0.000 claims abstract description 35
- 229920002472 Starch Polymers 0.000 claims abstract description 30
- 235000019698 starch Nutrition 0.000 claims abstract description 30
- 239000008107 starch Substances 0.000 claims abstract description 30
- 239000012153 distilled water Substances 0.000 claims abstract description 29
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 26
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims abstract description 22
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 22
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 24
- ARTYFIVUJGFUFS-UHFFFAOYSA-J [Mg+2].[K+].[K+].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(CN)N Chemical compound [Mg+2].[K+].[K+].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(C)(=O)[O-].C(CN)N ARTYFIVUJGFUFS-UHFFFAOYSA-J 0.000 claims description 23
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 21
- 210000000496 pancreas Anatomy 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 21
- 108010009004 proteose-peptone Proteins 0.000 claims description 21
- 230000001954 sterilising effect Effects 0.000 claims description 15
- 102000004142 Trypsin Human genes 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 239000012588 trypsin Substances 0.000 claims description 4
- 238000001514 detection method Methods 0.000 abstract description 5
- 238000000926 separation method Methods 0.000 abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract description 3
- 239000011780 sodium chloride Substances 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 abstract description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract 1
- 239000005018 casein Substances 0.000 abstract 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 abstract 1
- 235000021240 caseins Nutrition 0.000 abstract 1
- MUEOBEUHFKBRJH-UHFFFAOYSA-J magnesium;dipotassium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Mg+2].[K+].[K+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O MUEOBEUHFKBRJH-UHFFFAOYSA-J 0.000 abstract 1
- 238000009629 microbiological culture Methods 0.000 abstract 1
- 239000013630 prepared media Substances 0.000 abstract 1
- 239000012137 tryptone Substances 0.000 abstract 1
- 239000004474 valine Substances 0.000 abstract 1
- 244000025254 Cannabis sativa Species 0.000 description 21
- 239000000203 mixture Substances 0.000 description 13
- 241000894006 Bacteria Species 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 9
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 238000012856 packing Methods 0.000 description 9
- 241000193830 Bacillus <bacterium> Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000006286 aqueous extract Substances 0.000 description 6
- 238000010411 cooking Methods 0.000 description 6
- 208000006558 Dental Calculus Diseases 0.000 description 5
- 241001148134 Veillonella Species 0.000 description 5
- 244000005700 microbiome Species 0.000 description 5
- 241000605894 Porphyromonas Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 210000002421 cell wall Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000536 complexating effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- QLBHNVFOQLIYTH-UHFFFAOYSA-L dipotassium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [K+].[K+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O QLBHNVFOQLIYTH-UHFFFAOYSA-L 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000003752 polymerase chain reaction Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000012797 qualification Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- IOCJWNPYGRVHLN-MMALYQPHSA-N (2r)-2-amino-3-[[(2r)-2-amino-2-carboxyethyl]disulfanyl]propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CSSC[C@H](N)C(O)=O IOCJWNPYGRVHLN-MMALYQPHSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 241000142992 Acoraceae Species 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 235000013073 Acorus gramineus Nutrition 0.000 description 1
- 241000186045 Actinomyces naeslundii Species 0.000 description 1
- 208000010266 Aggressive Periodontitis Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 241000726221 Gemma Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000191992 Peptostreptococcus Species 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000223238 Trichophyton Species 0.000 description 1
- 241000893963 Trichophyton concentricum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 241000588902 Zymomonas mobilis Species 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 208000033608 aggressive 1 periodontitis Diseases 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000034391 chronic adult periodontitis Diseases 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical compound CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 101150004992 fadA gene Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 201000002266 mite infestation Diseases 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 238000011197 physicochemical method Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 235000000112 undernutrition Nutrition 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a selective medium with fusobacterium nucleatum, and belongs to field of microbial culture tests. The selective medium is characterized in that a 1000 ml prepared medium formula comprises casein tryptone, pea starch, yeast, sodium chloride, agar, ethylenediaminetetraacetic acid dipotassium magnesium salt, valine, gamma-amino butyric acid, sterile heat distortion calf serum, and the balance of distilled water. Compared with the prior art, the selective medium provided by the invention has the characteristics of being reliable in detection, and high in fusobacterium nucleatum separation rate.
Description
Technical field
The present invention relates to inspection microorganism culturing field, be specifically related to a kind of Fusobacterium nucleatum Selective agar medium.
Background technology
Microorganism culturing is a kind of technology making microbial growth by artificial means, and the substratum that selective medium is used to promote or suppress the organism (as cell or bacterium etc.) of certain type and designs, utilize this substratum required microorganism can be separated from the microorganism mixed.Periodontopathy is one of large class principal disease in oral cavity two, very high sickness rate is had in China, Fusobacterium nucleatum (Fusobacterium nucleatum, Fn) gram-negative obligate anaerobic bacillus(cillus anaerobicus) is belonged to, closely related with the inflammatory reaction of periodontal disease, being active microorganism in periodontopathy, is also one of putative pathogen of adult periodontitis and juvenile periodontitis.This bacterium, except can causing oral disease, also can cause the infection at other positions of health, comprises brain, lung and liver, blood and joint, chest and belly.At present, Fusobacterium nucleatum measuring means mainly subgingival plaque sampling carries out polymerase chain reaction (polymerase chain reaction, PCR) this kind of method needs to carry out DNA extraction and PCR primer design to sample, and need to be equipped with PCR related equipment, cost intensive, complicated operation.Laboratory is commonly used CDC anaerobic agar and is cultivated Fusobacterium nucleatum, because Clinical Laboratory In Grass Root Hospital lacks anaerobic inspection machine mostly, therefore multiplex greatly " anaerobism cylinder culture method ", so-called anaerobism cylinder is common dry cylinder, the cultivation of dry cylinder put into by flat board or the liquid nutrient medium test tube of having inoculated sample, exhaust oxygen in cylinder by physicochemical method, cause anaerobic environment.The oxygen depletion of anaerobism cylinder method needs the time, and Fusobacterium nucleatum is obligate anaerobic bacillus, therefore there is following defect in this kind of culture technique: the Fusobacterium nucleatum poor growth 1. in anaerobism cylinder on CDC anaerobic agar substratum, and positive rate is low, and within one week, qualification can be made more accurately in right and left; 2. due to non-absolute oxygen free condition, therefore in tartar sample, aerophil and facultative anaerobe have life condition, and substratum separating power is poor.In addition, be difficult to the Detection of Porphyromonas in tartar, Pu Shi bacillus, peptostreptococcus in existing CDC anaerobic agar culture medium culturing process, and Streptococcus hemolyticus, streptococcus mutans, Veillonella, streptococcus aureus, Yi Shi and the oral cavity such as actinomyces naeslundii, Candida albicans are resided bacterium and are separated, the growth affecting Fusobacterium nucleatum be separated.
Summary of the invention
Technical assignment of the present invention is for above the deficiencies in the prior art, provides a kind of Selective agar medium being suitable for Fusobacterium nucleatum growth.
The technical scheme that the present invention solves its technical problem is: a kind of Fusobacterium nucleatum Selective agar medium, is characterized in that, contains in the formula of preparation 1000ml substratum:
Pancreas casein peptone 5.0 ~ 10.0g;
Pea starch 2.0 ~ 5.0g;
Yeast powder 5.0 ~ 10.0g;
Sodium-chlor 5.0g;
Agar 15.0 ~ 20.0g;
Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 2 ~ 3g;
α-amino-isovaleric acid 0.1 ~ 0.5g;
γ-aminobutyric acid 0.01 ~ 0.1g;
Aseptic thermal distortion calf serum 50 ~ 100ml;
Distilled water adds to 1000ml.
Above-mentioned aseptic thermal distortion calf serum preparation method is: heat 10min at getting aseptic calf serum 80 DEG C, add sterilizing trypsin digestion 90min at 45 DEG C, and the mass ratio of enzyme-to-substrate is 1:150.
The preparation method of above-mentioned substratum is:
(1) pea starch is taken at 50 ~ 70 DEG C, gelatinization in 100ml distilled water;
(2) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid; γ-aminobutyric acid, mix with the pasted starch that distilled water dissolves afterwards and step (1) obtains, 121 DEG C, sterilizing 15min, is cooled to 45 DEG C, adds the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Described pancreas casein peptone contains various saccharides, amino acid, VITAMIN and trace element provides energy for Fusobacterium nucleatum grows, pea starch provides carbon source, the nutritive ingredients such as yeast powder rich in proteins, amino acid, polypeptide, Nucleotide, VITAMIN, somatomedin, trace element, promote the Growth and Reproduction of Fusobacterium nucleatum; Sodium-chlor maintains balanced osmotic pressure; Agar is the peptizer of substratum; α-amino-isovaleric acid is anerobe nutrition agent; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt provides the inorganic salt needed for Fusobacterium nucleatum growth, and the ethylenediamine tetraacetic acid dipotassium magnesium salt salt under this concentration is attached to bacteria cell wall by electrical complexing action, cellularstructure is caused to be out of shape, carry out playing antibacterial sterilization functions, and outer membrane protein OMP on Fusobacterium nucleatum cell walls and fadA adhesion protein make the cell wall area iso-electric point of Fusobacterium nucleatum not mate with ethylenediamine tetraacetic acid dipotassium magnesium salt salt, electrical complexing action is caused to lose efficacy, therefore antibacterial inefficacy.By experiment respectively by common for oral cavity anaerobe porphyromonas gingivalis Zymomonas mobilis, Pu Shi bacillus, Veillonella, Fusobacterium nucleatum inoculation is on the ethylenediamine tetraacetic acid dipotassium magnesium salt salt CDC anaerobic selection substratum adding 3g/L, control group is common CDC anerobe Selective agar medium, in 37 DEG C, observe after cultivating 48h in anaerobic jar, the substratum of interpolation EDTA Dipotassium salt finds small-sized Fusobacterium nucleatum translucent colony, do not find Detection of Porphyromonas, Pu Shi bacillus, Veillonella bacterium colony, control group substratum finds Detection of Porphyromonas, Pu Shi bacillus, Veillonella, Fusobacterium nucleatum bacterium colony, confirm that EDTA Dipotassium salt is to Detection of Porphyromonas thus, Pu Shi bacillus, Veillonella has good sterilization functions, and Fusobacterium nucleatum is had no significant effect.
Thermal distortion calf serum has optionally antibacterial effect, and its thermal distortion method is: heat 10min at getting aseptic calf serum 80 DEG C, adds sterilizing trypsin digestion 90min at 45 DEG C, and the mass ratio of enzyme-to-substrate is 1:150.Thermal distortion calf serum antibacterial properties is for aerophil, change aerophil cell wall structure on the one hand, cause permeability increase and dead, the redox-potential of substratum can be reduced on the other hand, promote oxygen-free environment and accelerate aerophil death, and this kind of anti-microbial effect is only directed to aerophil, then invalid for anerobe.By experiment same coli strain and Fusobacterium nucleatum bacterial strain are inoculated into respectively and with the addition of on the optimization CDC Selective agar medium of the thermal distortion calf serum of 80ml/L in CDC Selective agar medium and formula, cultivate at 37 DEG C, hermetically drying cylinder ring border, 24h, 48h identify, adding thermal distortion calf serum intestinal bacteria positive rate during 24h is 50%, and on the substratum not adding thermal distortion calf serum, intestinal bacteria positive rate is 80%; 48h detected result is add the substratum Fusobacterium nucleatum positive rate 70% of thermal distortion calf serum, Fusobacterium nucleatum positive rate 20% on the substratum not adding thermal distortion calf serum; Confirm that thermal distortion calf serum has good inhibition to aerophil in anaerobism cylinder thus, and promote that anerobe grows by accelerating oxygen-free environment.L-homoarginine is activator, promotes the absorption of α-amino-isovaleric acid; γ-aminobutyric acid is nutrient intensifier, promotes Fusobacterium nucleatum growth; Rhizome of Grass leaf Sweelflag (formal name used at school: Acorus gramineus) belongs to Acoraceae, and be graminoid per nnial herb, medicinal effects is rhizome position.Modern medicine study shows, Rhizome of Grass leaf Sweelflag is containing compositions such as volatile oil and carbohydrate, organic acid, amino acid, inorganic elements such as α-trans-Isoasarones, there are the effects such as swelling and pain relieving, waking up the patient from unconsciousness by dissipating phlegm, ulcer mange, Rhizome of Grass leaf Sweelflag Aqueous extracts is good nutrition-fortifying agent, Rhizome of Grass leaf Sweelflag water logging agent (1:3), all has restraining effect in various degree to dermatophytess such as trichophyton, Trichophyton concentricum, star-shaped nocardias in vitro.Have report to point out, Rhizome of Grass leaf Sweelflag decoction has the effect of killing ascites cells.The research such as Masuda T finds that the α-trans-Isoasarone in Rhizome of Grass leaf Sweelflag all has restraining effect to streptococcus aureus, Candida albicans, intestinal bacteria etc.Experiment confirms, Rhizome of Grass leaf Sweelflag water cooking liquid under 200g/L concentration there is no killing action for anerobe, take anaerobic culture medium as contrast, to add 200g/L Rhizome of Grass leaf Sweelflag water cooking liquid in Anaerobic culturel based formulas for experimental group, inoculation Fusobacterium nucleatum bacterial strain, the positive rate of 96h is respectively 60% and 70%, and the two compares no significant difference (P>0.05).
The present invention compared with prior art, has and detects the feature reliable, Fusobacterium nucleatum separation rate is high.
Embodiment
Below in conjunction with practical situation, the specific embodiment of the present invention is elaborated.
Embodiment 1, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 10.0g; Pea starch 2.0g; Yeast powder 5.0g; Sodium-chlor 5.0g; Agar 15.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 3g; α-amino-isovaleric acid 0.1g; Aseptic thermal distortion calf serum 100ml; Distilled water adds to 1000ml.Preparation method: (1) takes pea starch at 70 DEG C, gelatinization in 100ml distilled water; (2) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid, mix with the pasted starch that distilled water dissolves afterwards and step (1) obtains, 121 DEG C, sterilizing 15min, is cooled to 45 DEG C, adds the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Described aseptic thermal distortion calf serum preparation method heats 10min at getting aseptic calf serum 80 DEG C, adds sterilizing trypsin digestion 90min at 45 DEG C, and the mass ratio of enzyme-to-substrate is 1:150.Aseptic thermal distortion calf serum preparation method in other embodiments is in the same manner as in Example 1.
Embodiment 2, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 8.0g; Pea starch 5.0g; Yeast powder 8.0g; Sodium-chlor 5.0g; Agar 15.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 2.5g; α-amino-isovaleric acid 0.3g; L-homoarginine 0.1g; Aseptic thermal distortion calf serum 50ml; Distilled water adds to 1000ml.Preparation method: (1) takes pea starch at 50 DEG C, gelatinization in 100ml distilled water; (2) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid; L-homoarginine, mix with the pasted starch that distilled water dissolves afterwards and step (1) obtains, 121 DEG C, sterilizing 15min, is cooled to 45 DEG C, adds the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Embodiment 3, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 10.0g; Pea starch 3.0g; Yeast powder 10.0g; Sodium-chlor 5.0g; Agar 20.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 3g; α-amino-isovaleric acid 0.5g; γ-aminobutyric acid 0.01g; Aseptic thermal distortion calf serum 80ml; Distilled water adds to 1000ml.Preparation method: (1) takes pea starch at 70 DEG C, gelatinization in 100ml distilled water; (2) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid; γ-aminobutyric acid, mix with the pasted starch that distilled water dissolves afterwards and step (1) obtains, 121 DEG C, sterilizing 15min, is cooled to 45 DEG C, adds the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Embodiment 4, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 5.0g; Pea starch 5.0g; Yeast powder 8.0g; Sodium-chlor 5.0g; Agar 20.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 2g; α-amino-isovaleric acid 0.1g; Aseptic thermal distortion calf serum 80ml; 200g/L Rhizome of Grass leaf Sweelflag Aqueous extracts 200ml; Distilled water adds to 1000ml.Preparation method: (1) is got 40g Rhizome of Grass leaf Sweelflag and added water boil 30min, filters, gets filtrate, and adjustment volume is 200g/L to concentration, obtains Rhizome of Grass leaf Sweelflag water cooking liquid 200ml; (2) pea starch is taken at 60 DEG C, gelatinization in 100ml distilled water; (3) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid, mix with the pasted starch that distilled water dissolves afterwards and step (2) obtains, then add in the Rhizoma Acori Gramineii extract liquid of step (1) gained and mix 121 DEG C of sterilizing 15min, be cooled to 45 DEG C, add the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Embodiment 5, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 10.0g; Pea starch 2.0g; Yeast powder 5.0g; Sodium-chlor 5.0g; Agar 18.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 2.5g; α-amino-isovaleric acid 0.3g; L-homoarginine 0.3g; γ-aminobutyric acid 0.05g; Aseptic thermal distortion calf serum 80ml; Distilled water adds to 1000ml.Preparation method: (1) takes pea starch at 50 DEG C, gelatinization in 100ml distilled water; (2) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid; L-homoarginine; γ-aminobutyric acid, mix with the pasted starch that distilled water dissolves afterwards and step (1) obtains, 121 DEG C, sterilizing 15min, is cooled to 45 DEG C, adds the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Embodiment 6, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 5.0g; Pea starch 5.0g; Yeast powder 10.0g; Sodium-chlor 5.0g; Agar 20.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 2g; α-amino-isovaleric acid 0.3g; L-homoarginine 0.3g; Aseptic thermal distortion calf serum 80ml; The Rhizome of Grass leaf Sweelflag Aqueous extracts 250ml of concentration 200g/L; Distilled water adds to 1000ml.Preparation method: (1) is got 50g Rhizome of Grass leaf Sweelflag and added water boil 45min, filters, gets filtrate, and adjustment volume is 200g/L to concentration, obtains Rhizome of Grass leaf Sweelflag water cooking liquid 250ml; (2) pea starch is taken at 70 DEG C, gelatinization in 100ml distilled water; (3) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid; L-homoarginine, mix with the pasted starch that distilled water dissolves afterwards and step (2) obtains, then add in the Rhizoma Acori Gramineii extract liquid of step (1) gained and mix 121 DEG C of sterilizing 15min, be cooled to 45 DEG C, add the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Embodiment 7, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 8.0g; Pea starch 5.0g; Yeast powder 8.0g; Sodium-chlor 5.0g; Agar 15.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 2.5g; α-amino-isovaleric acid 0.3g; γ-aminobutyric acid 0.1g; Aseptic thermal distortion calf serum 50ml; The Rhizome of Grass leaf Sweelflag Aqueous extracts 300ml of concentration 200g/L; Distilled water adds to 1000ml.Preparation method: (1) is got 60g Rhizome of Grass leaf Sweelflag and added water boil 60min, filters, gets filtrate, and adjustment volume is 200g/L to concentration, obtains Rhizome of Grass leaf Sweelflag water cooking liquid 300ml; (2) pea starch is taken at 60 DEG C, gelatinization in 100ml distilled water; (3) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid; γ-aminobutyric acid, mix with the pasted starch that distilled water dissolves afterwards and step (2) obtains, then add in the Rhizoma Acori Gramineii extract liquid of step (1) gained and mix 121 DEG C of sterilizing 15min, be cooled to 45 DEG C, add the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Embodiment 8, contains in the formula of preparation 1000ml substratum: pancreas casein peptone 8.0g; Pea starch 3.0g; Yeast powder 10.0g; Sodium-chlor 5.0g; Agar 20.0g; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 3g; α-amino-isovaleric acid 0.3g; L-homoarginine 0.5g; γ-aminobutyric acid 0.01g; Aseptic thermal distortion calf serum 100ml; The Rhizome of Grass leaf Sweelflag Aqueous extracts 300ml of concentration 200g/L; Distilled water adds to 1000ml.Preparation method: preparation method: (1) is got 60g Rhizome of Grass leaf Sweelflag and added water boil 60min, filters, gets filtrate, and adjustment volume is 200g/L to concentration, obtains Rhizome of Grass leaf Sweelflag water cooking liquid 300ml; (2) pea starch is taken at 60 DEG C, gelatinization in 100ml distilled water; (3) pancreas casein peptone is taken; Yeast powder; Sodium-chlor; Agar; Ethylenediamine tetraacetic acid dipotassium magnesium salt salt; α-amino-isovaleric acid; L-homoarginine; The pasted starch distilled water that γ-aminobutyric acid and step (2) obtain dissolves, mixes, be dissolved in the Rhizoma Acori Gramineii extract liquid of step gained and mix 121 DEG C of sterilizing 15min, be cooled to 45 DEG C, add the mixing of aseptic thermal distortion calf serum, packing after sterile purified water constant volume to 1000ml.
Described Rhizome of Grass leaf Sweelflag Aqueous extracts concentration 200g/L refers to often liter containing crude drug 200g.
Gained Fusobacterium nucleatum substratum of the present invention is used for tartar sample, and have and detect the feature reliable, Fusobacterium nucleatum separation rate is high, be clinical data sufficient proof, pertinent data is as follows.
1 object and method.
1.1 medium preparing: experimental group establishes 5 groups altogether, are respectively embodiment 1 scheme group, embodiment 2 scheme group, embodiment 3 scheme group, embodiment 6 scheme group, embodiment 8 scheme group.Control group is common CDC anaerobic agar, and its formula is: pancreas casein peptone 15g/L, soy peptone 5g/L, yeast powder 5g/L; CYSTINE hydrochloride 0.4g/L; Agar 15g/L, sodium-chlor 5g/L, aseptic vitamin K 0.01g/L, aseptic protohemine 0.005g/L, aseptic Sheep Blood 50ml/L.
1.2 bacterial plaques gather cultural method: patients with periodontal disease 32 example, and every wet saliva, supragingival scaler removes supragingival calculus, after iodine tincture disinfection, gathers 2 diseased tooth subgingival plaques with aseptic Gracey curettage instrument.The bacterial plaque of collection is suspended in 1ml sterile saline, is inoculated in each experimental group and control group substratum with transfering loop sectional streak.At 37 DEG C, anaerobism cylinder is cultivated, and carries out identification of bacteria respectively at the tiny bacterium colony of 48h, 96h picking.Each sample number censorship PCR does molecular biology identification.
1.3 detect positive criteria: take out culture dish, and observe colony growth situation on substratum, thalline is elongated, and without gemma, two ends point, sometimes in long filament shape, bacterium colony is translucent, and edge is irregular.Check according to " clinical microbiology diagnosis and diagram ", net result gold standard is PCR qualification.
2 results: it is 29 examples that 32 parts of patients with periodontal disease tartar samples cultivate what be finally accredited as the Fusobacterium nucleatum positive through PCR.Each group of 48h detects the positive, false positive, feminine gender, false negative bacterial strain number of cases see the following form,
The above results can be found out, cultivate after 48 hours, each embodiment group and control group positive rate more all have pole notable difference (P<0.001).
Each group of 96h detects the positive, false positive, feminine gender, false negative bacterial strain number of cases see the following form,
The above results can be found out, cultivate after 96 hours, the positive rate of control group (CDC) increases, but each embodiment group compares with control group positive rate, all has notable difference (P<0.05).Each embodiment group compares with PCR detected result, positive rate no significant difference (P>0.05), and control group positive rate is then starkly lower than PCR detected result (P<0.001).
Above result shows, tartar sample is after cultivating in the dry cylinder of embodiment of the present invention substratum, occur during 48h rising appreciably, separation rate is apparently higher than existing substratum (CDC), after 96 hours, each embodiment and control group positive rate difference reduce, but difference still has statistical significance, each embodiment true positives recall rate detects with PCR and compares, no difference of science of statistics, and in common CDC anaerobic agar substratum anaerobism cylinder, cultivate under-nutrition, miscellaneous bacteria breeding rapidly, Fusobacterium nucleatum poor growth, although there is obvious bacterial strain Growth positive during 96h, but positive rate is still starkly lower than PCR detected result, do not play diagnostic effect.Substratum of the present invention is used for cultivating Fusobacterium nucleatum under dry cylinder ring border, and detect reliable, separation rate is high, thus the time is made a definite diagnosis in shortening.
Claims (1)
1. a Fusobacterium nucleatum Selective agar medium, is characterized in that containing in the formula of preparation 1000ml substratum:
Pancreas casein peptone 5.0 ~ 10.0g;
Pea starch 2.0 ~ 5.0g;
Yeast powder 5.0 ~ 10.0g;
Sodium-chlor 5.0g;
Agar 15.0 ~ 20.0g;
Ethylenediamine tetraacetic acid dipotassium magnesium salt salt 2 ~ 3g;
α-amino-isovaleric acid 0.1 ~ 0.5g;
γ-aminobutyric acid 0.01 ~ 0.1g;
Aseptic thermal distortion calf serum 50 ~ 100ml;
Distilled water adds to 1000ml;
Wherein said aseptic thermal distortion calf serum preparation method is: heat 10min at getting aseptic calf serum 80 DEG C, add sterilizing trypsin digestion 90min at 45 DEG C, and the mass ratio of enzyme-to-substrate is 1:150.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510343563.5A CN104862372A (en) | 2015-06-19 | 2015-06-19 | Selective medium with fusobacterium nucleatum |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510343563.5A CN104862372A (en) | 2015-06-19 | 2015-06-19 | Selective medium with fusobacterium nucleatum |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104862372A true CN104862372A (en) | 2015-08-26 |
Family
ID=53908545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510343563.5A Pending CN104862372A (en) | 2015-06-19 | 2015-06-19 | Selective medium with fusobacterium nucleatum |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104862372A (en) |
-
2015
- 2015-06-19 CN CN201510343563.5A patent/CN104862372A/en active Pending
Non-Patent Citations (3)
| Title |
|---|
| 廖香香: "EDTA 联合洗必泰对粪肠球菌抗菌作用的体外研究", 《中国优秀硕士学位论文全文数据库. 医药卫生科技辑》 * |
| 张振兴，姜平主编: "《实用兽医生物制品技术》", 31 May 1996 * |
| 段延华: "奥硝唑联用培氟沙星对牙周致病菌的抑菌作用及最佳配比研究", 《中国优秀博硕士学位论文全文数据库（硕士） 医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103409375B (en) | Virus diluent for inoculating chick embryo and preparation method of virus diluent | |
| CN103555641A (en) | Mycoplasma hyopneumoniae culture medium and preparation method thereof | |
| CN114129600A (en) | Novel application of composite probiotic preparation in anti-inflammatory product | |
| CN103160555A (en) | Culture medium, culture method and application of high-yield exotoxin of clostridium perfringens | |
| CN102533932B (en) | Prevotella intermedia (Pi) culture medium | |
| CN104046584A (en) | Bifidobacterium adolescentis bacteriocin as well as production method and special production strain of bifidobacterium adolescentis bacteriocin | |
| CN101911930A (en) | Transport fluid for culturing helicobacter pylori in gastric biopsy specimen and preparation method and application thereof | |
| CN104878070A (en) | Anaerobic culture medium for culturing fusobacterium necrophorum | |
| CN104862372A (en) | Selective medium with fusobacterium nucleatum | |
| CN104894213A (en) | Fn (fusobacterium nucleatum) culture medium for tartar specimen | |
| CN104862371A (en) | Tartar fusobacterium nucleatum selective medium | |
| CN109745555A (en) | A kind of mycoplasma hyopneumoniae and haemophilus parasuis bivalent inactivated vaccine and its application | |
| CN104894214A (en) | Fusobacterium necrophorum selective medium | |
| CN104845917A (en) | Enrichment culture medium | |
| CN104894215A (en) | Anaerobic culture medium | |
| CN102703568B (en) | Porphyromonas gingivalis culture medium for tartar specimen | |
| CN114129599A (en) | Application of silkworm chrysalis in the preparation of products for directional promotion of intestinal probiotics proliferation | |
| CN103397072B (en) | Candida selective culture medium for feces specimen and preparation method thereof | |
| CN102605037B (en) | Candida selection medium for stool specimens and preparation method thereof | |
| CN116590192B (en) | Helicobacter pylori solid separation culture medium and preparation method and application thereof | |
| CN103849673B (en) | MP (mycoplasma pneumoniae) culture and identification reagent and preparation method thereof | |
| CN105543326A (en) | Listerella selective culture medium | |
| CN104894216A (en) | Anaerobic bacillus culture medium applicable to fecal samples | |
| CN104862370A (en) | Bacteroides fragilis selective culture medium | |
| CN103397071B (en) | Candida selective culture medium for feces specimen and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150826 |